TSS
COGT icon

Two Sigma Securities’s Cogent Biosciences COGT Stock Holding History

Two Sigma Securities’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,428
Closed -$82.1K – 1484
2025
Q2 		$82.1K Buy
+11,428
New +$63.4K 0.01% 1064

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Two Sigma Securities's COGT Position: Q3 2025 in Review

Two Sigma Securities sold out of Cogent Biosciences (COGT) in Q3 2025, closing a stake of 11,428 shares — an estimated $82.1K sold.

Two Sigma Securities first reported a position in COGT in Q2 2025 and held it in 1 quarter. The position peaked at $82.1K in Q2 2025. 195 funds tracked by Wall St. Rank hold COGT as of Q3 2025.

  • Two Sigma Securities reported no remaining Cogent Biosciences position as of Q3 2025 after selling out during the quarter.
  • Two Sigma Securities sold 11,428 Cogent Biosciences shares in Q3 2025, an estimated $82.1K.
  • Two Sigma Securities first reported a position in Cogent Biosciences in Q2 2025 and held it in 1 quarter.
  • Two Sigma Securities's Cogent Biosciences position peaked at $82.1K in Q2 2025.
  • 195 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2025.

Based on Two Sigma Securities's 13F filing for Q3 2025, filed 14 Nov 2025.